Tuesday, February 18, 2020

Tuesday, February 18, 2020

PURDUE PHARMA LP: FDA Grants Competitive Generic Therapy (CGT) Designation to Purdue Pharma’s Investigational Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose

Purdue Pharma L.P issued the following announcement on April 24.

Purdue Pharma L.P. today announced that the U.S. Food & Drug Administration (FDA)’s Office of Generic Drugs has granted Competitive Generic Therapy (CGT) designation to nalmefene hydrochloride (HCl) injection, the company’s investigational opioid antagonist for the emergency treatment of known or suspected opioid overdose. This news follows the FDA’s recent Fast Track designation for nalmefene HCl, which was announced last month.

The FDA’s CGT designation allows for expedited review of generic versions of medications with inadequate generic competition, and is intended to help facilitate the timely market entry of generic drugs. The Fast Track and CGT designations are timely, as overdose deaths due to opioids continue to rise, driven by abuse of extremely potent and long-lasting synthetic opioid agonists, particularly illicitly manufactured fentanyl and its analogues.

“Purdue recognizes the immediate and critical need to treat potential fatal overdoses associated with opioid abuse and addiction,” said Craig Landau, MD, president and CEO, Purdue Pharma. “We are encouraged by FDA’s recent regulatory designations for nalmefene HCI, as we believe they acknowledge the urgent need for new and potentially more effective medications to address this public health emergency. Our company is committed to making this potentially life-saving treatment available as broadly and quickly as possible. As committed previously, if approved by FDA, Purdue and its subsidiaries will not profit from any future sales of nalmefene HCl injection.”

Nalmefene HCl has a longer duration of action than naloxone, another opioid antagonist currently approved for emergency treatment of known or suspected opioid overdose. If approved, the duration of effect of nalmefene HCl injection has the potential to serve as an important alternative for the treatment of opioid overdose. There is no guarantee that nalmefene HCl injection, an investigational agent, will successfully complete development or gain FDA approval.

“We are pleased the FDA has granted nalmefene HCl injection CGT designation, a decision that supports our common interest in making this important treatment option available as broadly and quickly as possible,” said Richard Fanelli, PhD, vice president, Regulatory Affairs, Imbrium Therapeutics L.P., a wholly-owned subsidiary of Purdue. “We are committed to working with the agency’s generic products division to provide an injectable generic version of nalmefene HCl.”

For additional information about Purdue’s commitment to addressing the opioid crisis, please read our open letter.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety.

Original source can be found here.

Organizations in this Story

Purdue Pharma L.P

More News

FDA Reporter